{"created":"2024-12-03T01:53:56.227999+00:00","id":2002045,"links":{},"metadata":{"_buckets":{"deposit":"4d809b71-2b5f-45a7-9238-6b629cba16f7"},"_deposit":{"created_by":8,"id":"2002045","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2002045"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02002045","sets":["1732778801467:1732778962699:1733190542397"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kobashi, Yurie","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shimazu, Yuzo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kawamura, Takeshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nishikawa, Yoshitaka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Omata, Fumiya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kaneko, Yudai","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kodama, Tatsuhiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tsubokura, Masaharu","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-sa/4.0/"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"IgG antibody against SARS-CoV-2 spike protein","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"BNT162b2 vaccination","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"COVID-19","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Adult","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Antibodies, Viral","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"BNT162 Vaccine","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"COVID-19","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"COVID-19 Vaccines","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Female","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Immunoglobulin G","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Male","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Middle Aged","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"SARS-CoV-2","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Spike Glycoprotein, Coronavirus","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Vaccination","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Vaccines","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants' work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test).","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"The Fukushima Society of Medical Science","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0016-2590","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2185-4610","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA0065246X","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"70","bibliographicPageStart":"67","bibliographicVolumeNumber":"68","bibliographic_titles":[{"bibliographic_title":"Fukushima Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.5387/fms.2021-28","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"35228456","subitem_relation_type_select":"PMID"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"2023116786","subitem_relation_type_select":"ICHUSHI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2022-04-15"}],"displaytype":"detail","filename":"FksmJMedSci_68_p67.pdf","filesize":[{"value":"188.3 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2002045/files/FksmJMedSci_68_p67.pdf"},"version_id":"8260f68a-047d-4ff2-97dc-1ae15e4284f2"}]},"item_title":"Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine","item_type_id":"40002","owner":"8","path":["1733190542397"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-04-15"},"publish_date":"2022-04-15","publish_status":"0","recid":"2002045","relation_version_is_last":true,"title":["Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2024-12-03T02:05:50.855013+00:00"}